Using genomic networks and in-silico approaches to identify actionable therapeutic targets, we identified and validated inhibitors of aurora kinases A and B as effective interceptors of lung adenocarcinoma progression, invasion in cells and in the mouse model of invasive lung cancer. Here, AURKA is linked to lung carcinoma.